Sun Pharma Makes Massive $12 Billion Binding Offer for US Firm Organon
Sun Pharma fell 4% after a $12B bid for Organon, raising debt worries despite strong cash and ongoing deal talks.
/ 1659 items
#XY↓
Wall Street Analysts Turn Bullish on 3 Promising Biotech Stocks (Buy Ratings)
Analysts see big upside in UroGen, Rapport, and Milestone, driven by strong drugs, upcoming data, and underestimated market potential.
Invivyd Drops Major Update: COVID Study on Track + New Measles Super-Antibody Discovered
Invivyd just announced major progress on its COVID-19 prevention study and a potential first-in-class measles antibody (VMS063).
Wolfe Research Initiates Coverage on Palisade Bio and Avalo Therapeutics with Strong Buy Calls
Wolfe Research: PALI “Outperform” ($7) eyes 2027 ulcerative colitis trial; AVTX “Outperform” ($48) waits May LOTUS Phase 2 readout.
MacroGenics’ LINNET Trial Back on Track After FDA Removes Partial Hold
FDA lifted hold on MacroGenics’ cancer study. New patients can join again; drug helps immune system fight tough ovarian cancers.
Assertio Agrees to $125 Million All-Cash Buyout by Garda Therapeutics
Assertio is being bought by Garda for $18/share + possible bonus if Sprix hits goals; deal closes June 2026, company goes private.